Compositions and methods are provided for reprogramming dermal fibroblasts to exhibit vasculogenic properties including the ability to stimulate vasculogenesis in vivo. In accordance with one embodiment such compositions are used in conjunction with standard treatment for use on chronic wounds including in diabetic patients.

The present disclosure provides, in part, a cell culture medium comprising a serum-free medium and one or more fibroblast growth factor (FGF) activators, a kit comprising the cell culture medium and instructions for use, methods of growing cells in vitro and of producing a cultured meat using the cell culture medium, and a cultured meat so produced.

The present disclosure methods, compositions and kits for the manufacture of extracellular matrix (ECM), wherein the methods compositions and kits comprise aspartyl alanyl diketopiperazine (DA-DKP).

Embodiments described herein relate generally to a three-dimensional ex vivo skeletal muscle tissue comprising a hydrogel and a plurality of cells that includes skeletal muscle cells, at least a portion of the cells being encapsulated inside the hydrogel. In some embodiments, the skeletal muscle tissue is characterized by one or more contractions in response to an electrical and/or chemical stimulation.

The present invention, in some aspects, provides compositions including a solution comprising a plurality of exfoliated silk microfibrils and/or exfoliated silk nanofibrils, wherein the micro- or nano-fibrils are characterized as having a substantially nematic structure, as well as methods for making and using the same.

The invention relates to a long term cell culturing method and a cell culturing apparatus and kit that employ a porous polyimide film. The invention further relates to a cell cryopreservation method and kit employing the porous polyimide film.

The disclosure encompasses the use of fibroblasts and products derived from fibroblasts for treatment of at least frontotemporal dementia. In particular embodiments, the disclosure teaches administration of cells intravenously, intrathecal or intracerebrally in order to reduce inflammation, enhance neurorgeneration and prevent neuronal dysfunction associated with progranulin abnormalities which characterize frontotemporal dementia. In particular embodiments, the disclosure teaches the utilization of exosomes, or apoptotic bodies derived from fibroblasts. In particular embodiments, the disclosure provides the use of genetically modified fibroblasts in order to augment therapy frontotemporal dementia.

Embodiments of the disclosure include methods of inhibiting and/or reversing blood vessel degeneration in an individual by administering to the individual a therapeutically effective amount of a fibroblast cell population. In specific embodiments, the individual has one or more aneurysms. Also disclosed are methods of inhibiting development of aortic dissection and/or reversing blood flow abnormalities associated with aortic dissection. In specific cases the cells are CD73 -positive and/or CD56-positive.

The present invention describes a method for increasing transfection efficiency of cells. The present invention further provides a method for increasing the efficiency of stem cell reprogramming.

6,8-Disubstituted-9-(heterocyclyl)purines for use in pharmaceutical and cosmetic compositions and applications are provided. These 6,8-disubstituted-9-(heterocyclyl)purines have a wide range of biological activities, including for example antioxidant, anti-inflammatory, anti-senescent, anti-aging, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. Compositions may include additional excipients and auxiliary substances. Methods of treatment of animals, mammals, plants, cells, yeast, and cells in tissue culture are also disclosed.